Skip to main content
OpenTrials
Completed

NCT Number: NCT05080933

ECMO for COVID-19 vs Influenza A H1N1 Associated ARDS

Objective: Veno-venous ECMO has been used as a rescue therapy for patients with severe ARDS associated to influenza A H1N1 and COVID19 viral pneumonia. Little is known about outcome of these patients who required extracorporeal support.

Research question: To compare outcome of patients who required VV ECMO for Covid19 and H1N1 associated ARDS

Completed

Looking for future studies?

Notify Me

Key information

Conditions

ARDS COVID-19 Coronaviridae Infections Coronavirus Infections H1N1 Influenza Infections Lung Diseases Nidovirales Infections Orthomyxoviridae Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Turin - Azienda Ospedaliera Città della Salute e della Scienza di Torino

Turin, 10126, Italy

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • COVID-19 or influenza A H1N1 (suspected or confirmed) diagnosis
  • Severe ARDS (according to Berlin Definition)
  • VV ECMO
  • Invasive mechanical ventilation through endotracheal tube or tracheostomy

Exclusion criteria

  • Age<18 years

Treatment and study plan

Primary outcomes

  1. All cause mortality on day 60 after ECMO initiation

    Time frame: 60 days

Secondary outcomes

  1. Hospital length of stay

    Time frame: 90 days

  2. ICU length of stay

    Time frame: 90 days

  3. Hospital mortality on day 90 after ECMO initiation

    Time frame: 90 days

  4. ECMO duration

    Time frame: 90 days

  5. ECMO associated hemorrhagic complications

    Time frame: 60 days

  6. ECMO associated mechanical complications

    Time frame: 60 days

  7. Invasive mechanical ventilation duration

    Time frame: 90 days

  8. ECMO related haemorrhagic complications

    Time frame: 90 days

  9. ECMO related mechanical complications

    Time frame: 90 days

Sponsors and collaborators

Lead sponsor

University of Turin, Italy

Other

Registry information

Official study title

Extracorporeal Membrane Oxygenation for COVID-19 and Influenza H1N1 Associated Acute Respiratory Distress Syndrome: a Multi-centre Retrospective Cohort Study

Acronym: InfluCOV_ECMO

Important dates

Study start
2009
Primary completion
2021
Study completion
2021
First posted
Oct 18, 2021
Registry last updated
Oct 18, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.